MarkusF.RenschlerMD

Oncology • Stanford, CA

Physician

Join to view full profile

Are you Dr. Renschler?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 35 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
300 Pasteur Dr
Stanford, CA 94305
Phone+1 650-723-4000

Summary

Dr. Markus Renschler, MD is an oncologist in Stanford, California. He is currently licensed to practice medicine in California. He is affiliated with Stanford Health Care.

Education & Training

Stanford Health Care-Sponsored Stanford UniversityInternship, Internal Medicine, 1988 - 1989
Stanford University School of MedicineClass of 1988

Certifications & Licensure

CA State Medical License 1989 - 2026

Clinical Trials

Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Brain Metastases Start of enrollment: 1998 Aug 01
Completed
Phase 3
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer Start of enrollment: 2002 Feb 01
Completed
Phase 1
AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy Start of enrollment: 2007 Sep 01
Completed
Phase 3
A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors. Start of enrollment: 2009 Jun 01
Completed
Phase 1
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors Start of enrollment: 2019 Oct 09
Active, not recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

5 citations
18F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer.
Ronald L. Korn, Daniel D. Von Hoff, Mitesh J. Borad, Markus F. Renschler, Desmond McGovern
Cancer Imaging. 2017-08-03
22 citations
Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory Analysis From a Phase 3 Study
Volker Kunzmann, Ramesh K. Ramanathan, David Goldstein, Helen Liu, Stefano Ferrara
Pancreas. 2017-02-01
4 citations
Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Pa...
Vera Hirsh, Amy Ko, Richard Pilot, Markus F Renschler, Mark A Socinski
Clinical Lung Cancer. 2016-09-01

Press Mentions

CYT-0851 Phase 1 Dose Escalation Results Show Early Clinical Activity and Generally Well Tolerated Safety Profile in Advanced Solid Tumors and Hematologic MalignanciesJune 5th, 2022
Cyteir Therapeutics Announces the Appointment of Dr. Jeffrey S. Humphrey to Board of DirectorsDecember 16th, 2021
Cyteir Therapeutics Selected to Join Russell 2000® IndexSeptember 20th, 2021
Join now to see all